Bristol-Myers Squibb Company (NYSE:BMY) has been assigned a $65.00 price objective by analysts at Cowen and Company in a research report issued on Monday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Cowen and Company’s price objective would suggest a potential upside of 12.32% from the stock’s current price.

Several other equities analysts have also commented on BMY. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Wednesday, May 3rd. Robert W. Baird initiated coverage on Bristol-Myers Squibb in a report on Tuesday, April 25th. They issued an “outperform” rating on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective on the stock in a report on Monday, June 5th. Finally, BidaskClub downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Buy” and a consensus price target of $62.12.

Bristol-Myers Squibb (NYSE:BMY) opened at 57.87 on Monday. The company has a market capitalization of $94.90 billion, a P/E ratio of 21.14 and a beta of 1.17. The firm has a 50-day moving average price of $55.86 and a 200 day moving average price of $54.87. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $60.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the business earned $0.69 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, equities analysts predict that Bristol-Myers Squibb will post $2.97 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (BMY) PT Set at $65.00 by Cowen and Company” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/16/bristol-myers-squibb-company-bmy-pt-set-at-65-00-by-cowen-and-company.html.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.23% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Blue Chip Partners Inc. increased its position in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 15 shares during the last quarter. Keel Point LLC increased its position in Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares during the last quarter. Staley Capital Advisers Inc. increased its position in Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the last quarter. Finally, Shayne & CO. LLC increased its position in Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 24 shares during the last quarter. 69.68% of the stock is owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.